- Home
- LEGN vs LNTH Comparison
LEGN vs LNTH Comparison
Compare LEGN & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGN
- LNTH
- Stock Information
- Founded
- LEGN 2014
- LNTH 1956
- Country
- LEGN United States
- LNTH United States
- Employees
- LEGN N/A
- LNTH N/A
- Industry
- LEGN Biotechnology: Pharmaceutical Preparations
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LEGN Health Care
- LNTH Health Care
- Exchange
- LEGN Nasdaq
- LNTH Nasdaq
- Market Cap
- LEGN 7.0B
- LNTH 7.5B
- IPO Year
- LEGN 2020
- LNTH 2015
- Fundamental
- Price
- LEGN $32.80
- LNTH $101.32
- Analyst Decision
- LEGN Strong Buy
- LNTH Strong Buy
- Analyst Count
- LEGN 12
- LNTH 6
- Target Price
- LEGN $79.00
- LNTH $129.83
- AVG Volume (30 Days)
- LEGN 1.6M
- LNTH 830.2K
- Earning Date
- LEGN 05-12-2025
- LNTH 05-01-2025
- Dividend Yield
- LEGN N/A
- LNTH N/A
- EPS Growth
- LEGN N/A
- LNTH N/A
- EPS
- LEGN N/A
- LNTH 4.36
- Revenue
- LEGN $627,241,000.00
- LNTH $1,533,910,000.00
- Revenue This Year
- LEGN $66.92
- LNTH $5.74
- Revenue Next Year
- LEGN $51.77
- LNTH $12.27
- P/E Ratio
- LEGN N/A
- LNTH $23.24
- Revenue Growth
- LEGN 119.97
- LNTH 18.32
- 52 Week Low
- LEGN $29.27
- LNTH $61.47
- 52 Week High
- LEGN $60.87
- LNTH $126.89
- Technical
- Relative Strength Index (RSI)
- LEGN 45.92
- LNTH 55.37
- Support Level
- LEGN $29.27
- LNTH $91.65
- Resistance Level
- LEGN $35.11
- LNTH $104.00
- Average True Range (ATR)
- LEGN 1.89
- LNTH 5.54
- MACD
- LEGN 0.16
- LNTH 0.34
- Stochastic Oscillator
- LEGN 60.48
- LNTH 85.89
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.